Antibodies represent a rapidly growing therapeutic modality, demonstrating clinical success over a wide variety of diseases, including cancer, autoimmune disorders, and infections. Their ability to bind with high specificity and their inherent stability enable a targeted therapeutic approach, minimising off-target effects and reducing drug-drug interactions. Recent advances in technologies for the development of antibodies are further driving this growth, accelerating the discovery process through the rapid generation and screening of antibody candidates.

Phage Display Technology for the Identification and Development of Therapeutic Antibodies Phage display technology has played a crucial role in the discovery and optimisation of antibodies for a wide range of clinical and research applications, with the greatest impact seen in the development of antibody-based drugs. This well-established approach enables the identification of fully human therapeutic monoclonal antibodies (mAbs) from a diverse collection of antibody fragments presented on the surface of bacteriophages, known as a phage display library.